Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02669082
Other study ID # Ramelteon-4002
Secondary ID JapicCTI-163143U
Status Completed
Phase Phase 4
First received
Last updated
Start date May 9, 2017
Est. completion date January 31, 2018

Study information

Verified date May 2019
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.


Description:

The drug being tested in this study is called ramelteon. Ramelteon is being tested to treat people who have insomnia with depression. This study will look at sleep activity of participants who take ramelteon.

The study will enroll approximately 30 patients. Participants will be administered:

• Ramelteon 8 mg

Participants will be asked to take 1 tablet orally at bedtime. This multi-center study will be conducted in Japan. The overall period to participate in this study is 9 weeks (Run-in period for 1 week and treatment period for 8 weeks). Participants will make multiple visits to clinic including the final visit 8 weeks after the start of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 31, 2018
Est. primary completion date January 31, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 64 Years
Eligibility Inclusion Criteria:

1. Has difficulty in initiating sleep at least 3 days per week for at least 4 weeks at the time of informed consent.

2. Has Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)-defined depression.

3. Man or woman between 20 and 64 years of age, inclusive, at the time of informed consent.

4. Outpatient.

5. Meets either of the following criteria based on the 17-item Hamilton Rating Scale for Depression (HAM-D17) both at the start of the run-in period and the start of the study treatment period: has a score of 2 for "6: Insomnia Early", or has a score of 1 for "6: Insomnia Early" AND a score of at least 3 in total for "7: Insomnia Middle" and "8: Insomnia Late".

6. Has a total HAM-D17 score of 16 or under both at the start of the run-in period and the start of the study treatment period.

7. Under treatment of the same antidepressant agents on a stable dose for at least 4 weeks before the start of the run-in period.

8. Goes to bed routinely in a daily life (time for bed between 21.00 p.m. and 1.00 a.m. at least 4 days per week).

9. Actigraphy shows at least 3 days with sleep latency 30 minutes or longer AND total nocturnal sleep time 6.5 hours or shorter on the same day during the run-in period.

10. In the opinion of the principal investigator or investigator, is capable of understanding the contents of the study and complying with study requirements.

11. Is capable of signing and dating the informed consent form in person before any study procedures.

Exclusion Criteria:

1. Has a history of hypersensitivity to ramelteon and melatonin.

2. Has severe liver disorder.

3. Took ramelteon within 4 weeks before the informed consent.

4. Using any insomnia medications (including investigational drugs and unapproved drugs) for 2 weeks before the treatment period.

5. Shift worker or night worker.

6. Has complications of psychiatric or neurological diseases that affect sleep state other than depression.

7. Has a HAM-D17 score of at least 1 for"11: Suicide" at the start of the run-in period or the start of the study treatment period, or any suicide attempts within 24 weeks before or during the run-in period.

8. Pregnant woman, nursing mother, or woman who plans to become pregnant or donate eggs before the informed consent, during the study period or within 4 weeks after the end of the study.

9. Is participating in any other investigational or post-marketing clinical trial/study.

10. For other reason, judged not appropriate for participation in this study by the principal investigator or investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ramelteon
Ramelteon tablets

Locations

Country Name City State
Japan You Ariyoshi Sleep Clinic Kitakyushu Fukuoka
Japan Senzoku Psychosomatic Clinic Meguro Tokyo
Japan Ishikawa Mental Clinic Sapporo Hokkaido
Japan Minami 1jo Mental Clinic Sapporo Hokkaido
Japan Sangenjaya Neurology and Psychosomatic Clinic Setagaya Tokyo
Japan Himorogi Kokorono Clinic Shinjuku Tokyo
Japan Seiwa Hospital Shinjuku Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Actigraphy-Measured Sleep Latency at the End of the Treatment Period Sleep latency was defined as time period measured from "lights out," or bedtime, to the beginning of sleep. Sleep latency was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days was evaluated. A negative change from Baseline indicates improvement. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Diary-Measured Sleep Latency at the End of the Treatment Period Sleep latency was defined as time period measured from "lights out," or bedtime, to the beginning of sleep. Sleep latency was recorded by the participant in a diary. Mean value from the past 7 days at each timepoint was evaluated. A negative change from Baseline indicates improvement. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Actigraphy-Measured Total Nocturnal Sleep Time at the End of the Treatment Period Total nocturnal sleep time was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Total nocturnal sleep time by actigraphy was total time in bed from which sleep latency, nocturnal wake time, and the time from waking up to leaving the bed were subtracted. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Actigraphy-Measured Nocturnal Wake Time at the End of the Treatment Period Nocturnal wake time is the total time that is scored between nocturnal sleep onset and final wake-up. Nocturnal wake time was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates a worsening. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Actigraphy-Measured Number of Nocturnal Awakenings at the End of the Treatment Period The number of nocturnal awakenings were assessed by actigraphy which is a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days at each time point was evaluated. A positive change from Baseline indicates a worsening. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Actigraphy-Measured Sleep Efficiency at the End of the Treatment Period Sleep efficiency was defined as percentage of sleep in the period potentially filled by sleep-ratio of total sleep time to time in bed calculated as [(Total sleep time/total time in bed) * 100]. Sleep efficiency was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Diary-Measured Total Nocturnal Sleep Time at the End of the Treatment Period Total nocturnal sleep time by diary was calculated as total time in bed (awaking hour - bedtime hour) from which sleep latency was subtracted. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Diary-Measured Number of Nocturnal Awakenings at the End of the Treatment Period The number of nocturnal awakenings were recorded by the participant in a diary. Mean value from the past 7 days at each timepoint was evaluated. A negative change from Baseline indicates improvement. Baseline and the end of the Treatment Period (up to Week 8)
Secondary Change From Baseline in Actigraphy-Measured Daytime Activity Level, as Evaluated by the Number of Footsteps, at the End of the Treatment Period Daytime activity level, as evaluated by the number of footsteps, were assessed by actigraphy, a non-intrusive tool that measures an individual's movement. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement. Baseline and the end of the Treatment Period (up to Week 8)
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A